TEANECK, N.J., Jan. 26, 2015 (GLOBE NEWSWIRE) -- Phibro Animal Health Corporation (Nasdaq:PAHC) today announced it has entered into a long-term global license arrangement with Merial SAS (Lyon, France) to share in the use of Phibro's vaccine delivery technology for use in animal vaccines. The agreement was signed in 2012 and is being announced today following Merial's receipt of marketing authorization in France for an avian vaccine product utilizing the licensed technology.
The patented technology utilizes an innovative effervescent tablet that contains a freeze-dried sterile vaccine virus, packaged in sealed aluminum blister packages. The technology replaces the glass vials that are in common use today, and offers major advantages in a number of areas including storage requirements, customer handling and disposal.
Under the arrangement, use of the technology will be limited to Merial, Phibro and their affiliates.
"Merial is excited to partner with Phibro and is looking forward to bringing the benefits of this break-through technology to Merial's poultry producer customers," said Jerome Baudon, Global Head of Merial's Avian Business.
Larry Miller, President, Animal Health, Phibro, commented, "For more than 10 years our vaccine business has been focused on creating innovative solutions to best serve the needs of our customers - this Phibro technology is another strong example of how that focus continues to yield great products and platforms and we are very happy to be able to now expand the global reach of Phibro technology through Merial, a leader in animal vaccines around the world."
About Phibro Animal Health Corporation
Phibro Animal Health Corporation is a diversified global developer, manufacturer and marketer of a broad range of animal health and mineral nutrition products for use in the production of poultry, swine, cattle, dairy and aquaculture, with annual sales in excess of $700 million. For further information, please visit www.pahc.com.
Merial is a world-leading, innovation-driven animal health company, providing a comprehensive range of products to enhance the health, well-being and performance of a wide range of animals. Merial employs around 6,200 people and operates in more than 150 countries worldwide with more than €2 billion of sales. Merial is a Sanofi company. For further information, please visit www.merial.com.
CONTACT: Phibro Animal Health Corporation
Chief Financial Officer